Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established it as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The Company products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Company profile
Ticker
ILMN
Exchange
Website
CEO
Francis deSouza
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Bio-Rad Laboratories • Waters • Avantor • Mettler-Toledo International • Bruker • Perkinelmer • Seer • Cue Health • Cytek BioSciences ...
Former names
ILLUMINA INC
SEC CIK
Corporate docs
Subsidiaries
Advanced Liquid Logic Inc. • BlueBee Belgium BVBA • BlueBee Holding BV • Conexio Genomics Pty Ltd. • Emedgene Technologies Ltd • GRAIL, LLC • IDbyDNA Inc. • Illumina AB • Illumina Australia • Illumina Austria GmbH ...
IRS number
330804655
ILMN stock data
Analyst ratings and price targets
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
24 Mar 23
DFAN14A
Additional proxy materials by non-management
24 Mar 23
DEFA14A
Additional proxy soliciting materials
20 Mar 23
DFAN14A
Additional proxy materials by non-management
15 Mar 23
DEFA14A
Additional proxy soliciting materials
13 Mar 23
DEFA14A
Additional proxy soliciting materials
13 Mar 23
DFAN14A
Additional proxy materials by non-management
13 Mar 23
S-8
Registration of securities for employees
1 Mar 23
10-K
2022 FY
Annual report
17 Feb 23
8-K
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022
7 Feb 23
Transcripts
ILMN
Earnings call transcript
2022 Q4
7 Feb 23
ILMN
Earnings call transcript
2022 Q3
4 Nov 22
ILMN
Earnings call transcript
2022 Q2
11 Aug 22
ILMN
Earnings call transcript
2022 Q1
6 May 22
ILMN
Earnings call transcript
2021 Q4
11 Feb 22
ILMN
Earnings call transcript
2021 Q3
5 Nov 21
ILMN
Earnings call transcript
2021 Q2
6 Aug 21
ILMN
Earnings call transcript
2021 Q1
28 Apr 21
ILMN
Earnings call transcript
2020 Q4
12 Feb 21
ILMN
Earnings call transcript
2020 Q3
29 Oct 20
Latest ownership filings
Financial summary
| Quarter (USD) | Jan 23 | Oct 22 | Jul 22 | Apr 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jan 23 | Jan 22 | Jan 21 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.01 bn | 2.01 bn | 2.01 bn | 2.01 bn | 2.01 bn | 2.01 bn |
| Cash burn (monthly) | (no burn) | (no burn) | 56.00 mm | 357.75 mm | (no burn) | (no burn) |
| Cash used (since last report) | n/a | n/a | 159.75 mm | 1.02 bn | n/a | n/a |
| Cash remaining | n/a | n/a | 1.85 bn | 990.47 mm | n/a | n/a |
| Runway (months of cash) | n/a | n/a | 33.1 | 2.8 | n/a | n/a |
Institutional ownership, Q4 2022
92.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 913 |
| Opened positions | 137 |
| Closed positions | 99 |
| Increased positions | 312 |
| Reduced positions | 337 |
| 13F shares | Current |
|---|---|
| Total value | 28.45 tn |
| Total shares | 145.84 mm |
| Total puts | 1.36 mm |
| Total calls | 1.28 mm |
| Total put/call ratio | 1.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Baillie Gifford & Co | 16.74 mm | $3.39 tn |
| Vanguard | 13.02 mm | $2.63 tn |
| BLK Blackrock | 12.05 mm | $2.44 tn |
| STT State Street | 6.65 mm | $1.34 tn |
| Edgewood Management | 6.48 mm | $1.31 tn |
| MS Morgan Stanley | 5.11 mm | $1.03 tn |
| Polen Capital Management | 5.05 mm | $1.02 tn |
| Growth Fund Of America | 4.99 mm | $1.50 bn |
| Wellington Management | 4.07 mm | $822.93 bn |
| Alliancebernstein | 3.87 mm | $782.39 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mar 23 | Alexander Aravanis | Common Stock | Grant | Acquire A | No | No | 0 | 10,074 | 0.00 | 12,996 |
| 1 Mar 23 | Alexander Aravanis | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 6,045 | 0.00 | 6,045 |
| 1 Mar 23 | Alexander Aravanis | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 4,030 | 0.00 | 4,030 |
| 1 Mar 23 | Charles Dadswell | Common Stock | Grant | Acquire A | Yes | No | 0 | 6,926 | 0.00 | 16,967 |
| 1 Mar 23 | Charles Dadswell | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 4,156 | 0.00 | 4,156 |
| 1 Mar 23 | Charles Dadswell | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 2,771 | 0.00 | 2,771 |
| 1 Mar 23 | Francis A deSouza | Common Stock | Grant | Acquire A | No | No | 0 | 31,480 | 0.00 | 120,992 |
| 1 Mar 23 | Francis A deSouza | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 18,888 | 0.00 | 18,888 |
| 1 Mar 23 | Francis A deSouza | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 12,592 | 0.00 | 12,592 |
| 1 Mar 23 | Scott D Ericksen | Common Stock | Grant | Acquire A | No | No | 0 | 1,637 | 0.00 | 7,950 |
News
Individual Stock Picks As The Fed Tightens Financial Conditions Further Despite Banking Stress
24 Mar 23
Binance Suspends Trading, European Bank Trouble, Twitter To Remove Legacy Verified Checkmarks: Today's Top Stories
24 Mar 23
Carl Icahn Steps Up Battle With Illumina, Says Directors Asked Additional Insurance For Grail Deal
24 Mar 23
Financial Times Reported Earlier: Carl Icahn Says Illumina Directors Demanded Extra Insurance For Grail Deal
24 Mar 23
A Look Into Illumina's Debt
22 Mar 23
Press releases
Illumina Issues Statement in Response to Carl Icahn's Letter
24 Mar 23
Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements
20 Mar 23
Illumina launches its first product enabling long- and short-read sequencing on one instrument
14 Mar 23
Illumina Responds to Icahn Partners' Nomination of Directors
13 Mar 23
Thinking about trading options or stock in Illumina, NVIDIA, Tesla, Wells Fargo, or Amazon?
13 Mar 23